Verified factor-similar pair

OMFS vs QVMM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
84
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • QVMM has the higher backtested relative Sharpe (1.065 vs 0.951).
  • QVMM has the lower published fee (0.15% vs 0.39%).
  • QVMM is cheaper on dividend valuation (120 vs 137, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

OMFS

Invesco Russell 2000 Dynamic Multifactor ETF
SMB
Adj. R2
0.941
Rel. Sharpe
0.951
Mkt beta
0.93
AUM
US$269M
MER
0.39%
Valuation
137

QVMM

Invesco S&P MidCap 400 QVM Multi-factor ETF
SMB
Adj. R2
0.940
Rel. Sharpe
1.065
Mkt beta
1.01
AUM
US$392M
MER
0.15%
Valuation
120

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
OMFS
+0.85
|t|
+13.5
QVMM
+0.59
|t|
+8.6
diff +0.26
HML
OMFS
+0.17
|t|
+3.1
QVMM
+0.16
|t|
+2.2
diff +0.02
RMW
OMFS
+0.01
|t|
+0.1
QVMM
+0.20
|t|
+3.1
diff -0.19
CMA
OMFS
+0.15
|t|
+1.9
QVMM
+0.10
|t|
+1.1
diff +0.06
UMD
OMFS
-0.01
|t|
-0.3
QVMM
+0.03
|t|
+0.6
diff -0.04

Why This Pair Matches

Exposure level
82
Exposure shape
98
Mkt beta diff
0.07
Rel. Sharpe diff
0.114

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

OMFS fund page QVMM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.